Epizyme Files for IPO, Aims for $69M for Epigenetics Platform
By Jennifer Boggs
Monday, April 29, 2013
Epizyme Inc., the latest biotech to take advantage of the emerging growth company provision in last year's JOBS Act, filed an S-1 Friday for a proposed $69 million initial public offering (IPO), though the number of shares and share price have not yet been disclosed.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.